Physician profile
Michael Christopher Kruer
NPI 1366640468
$73,273.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.43 · 2020: $3.58 · 2021: $19K · 2022: $11K · 2023: $35K · 2024: $7,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $19K · Travel and Lodging: $3,396 · Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,875.00 |
| Consulting Fee | $19,150.00 |
| Travel and Lodging | $3,396.16 |
| Food and Beverage | $903.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $49,172.11 | 2021-2024 | Emflaza |
| Neurocrine Biosciences, INC. | $16,348.10 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $3,843.73 | 2022-2024 | Daybue |
| Merz Pharmaceuticals, LLC | $3,587.50 | 2021 | |
| Immedica Pharma US, INC. | $102.67 | 2023 | |
| Ucb, INC. | $75.35 | 2022-2023 | Nayzilam |
| Sunovion Pharmaceuticals INC. | $40.11 | 2019 | |
| Eisai INC. | $33.75 | 2019 | |
| Orphalan INC | $27.30 | 2023 | Cuvrior |
| Neurelis, INC. | $15.57 | 2022 | |
| Horizon Therapeutics Plc | $14.86 | 2023 | Uplizna |
| Travere Therapeutics, INC. | $12.81 | 2019-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kruer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.